ORMP stock forecast
Our latest prediction for Oramed Pharmaceuticals, Inc.'s stock price was made on the July 11, 2018 when the stock price was at 5.95$.
In the short term (2weeks), ORMP's stock price should outperform the market by 2.22%. During that period the price should oscillate between -8.42% and +13.33%.
In the medium term (3months), ORMP's stock price should outperform the market by 1.85%. During that period the price should oscillate between -20.35% and +34.50%.Get email alerts
Create a solid portfolio with ORMP
About Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -0.86$ per share.
The book value per share is 0.96$
Three months stock forecastJuly 11, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|